Oncothyreon Appoints Scott D. Myers Chief Executive Officer
March 29, 2016 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, March 29, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products to improve the lives and...
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium
December 08, 2015 16:05 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the...
Oncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer Patients
December 02, 2015 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the...